APTEVO THERAPEUTICS FILES 8-K ON SHAREHOLDER VOTE MATTERS

TL;DR

**APVO filed an 8-K about submitting matters to a shareholder vote.**

AI Summary

Aptevo Therapeutics Inc. filed an 8-K on February 5, 2024, to report the submission of matters to a vote of security holders. This filing indicates that the company is engaging its shareholders on important corporate decisions, which is a standard governance practice. For investors, this means Aptevo is moving forward with actions that require shareholder approval, potentially impacting future operations or capital structure.

Why It Matters

This filing signals that Aptevo Therapeutics is progressing with corporate actions that require shareholder input, which could influence the company's strategic direction and financial health.

Risk Assessment

Risk Level: low — This 8-K is a routine disclosure about shareholder voting, indicating standard corporate governance without immediate negative implications.

Analyst Insight

A smart investor would monitor subsequent filings (like proxy statements) to understand the specific matters being voted on by security holders, as these could reveal strategic shifts or capital allocation decisions by Aptevo Therapeutics Inc.

Key Players & Entities

• Aptevo Therapeutics Inc. (company) — the registrant filing the 8-K
• February 05, 2024 (date) — date of earliest event reported
• Delaware (company) — state of incorporation for Aptevo Therapeutics Inc.
• 001-37746 (dollar_amount) — Commission File Number for Aptevo Therapeutics Inc.
• 81-1567056 (dollar_amount) — IRS Employer Identification No. for Aptevo Therapeutics Inc.
• APVO (company) — trading symbol for Aptevo Therapeutics Inc.
• The Nasdaq Stock Market LLC (company) — exchange where Aptevo Therapeutics Inc. Common Stock is registered

FAQ

Key Financial Figures

• $0.001 — nge on which registered Common Stock, $0.001 par value APVO The Nasdaq Stock Mar

Filing Documents

• apvo-20240205.htm (8-K) — 50KB
• 0000950170-24-011766.txt ( ) — 164KB
• apvo-20240205.xsd (EX-101.SCH) — 25KB
• apvo-20240205_htm.xml (XML) — 5KB

07 Submission of Matters to a Vote of Security Holders

Item 5.07 Submission of Matters to a Vote of Security Holders. On February 5, 2024, Aptevo Therapeutics Inc. (the "Company") held a Special Meeting of Stockholders (the "Special Meeting"), at which the Company's stockholders: (1) Approved an amendment to the Company's Amended and Restated Certificate of Incorporation to effect a reverse stock split of the Company's common stock at a ratio in the range of 1-for-15 to 1-for-44, with such ratio to be determined in the discretion of the Board of Directors of the Company (the "Board") and with such reverse stock split to be effected at such time and date, if at all, as determined by the Board in its sole discretion (Proposal 1); (2) Approved, in accordance with Nasdaq Listing Rule 563(d), the issuance of more than 19.99% of the Company's outstanding common stock, par value $0.001 per share, issuable upon the exercise of New Series A-2 Warrants and New Series B-2 Warrants with the right for such potential exercise to occur immediately following the date upon which stockholders approve this proposal (Proposal 2); and (3) Approved an authorization to adjourn the Special Meeting, if necessary or appropriate, to solicit additional proxies if there are not sufficient votes in favor of Proposal 1 or Proposal 2. The tables below set forth the results of the vote of the Company's stockholders for the Special Meeting. Proposal 1: To approve an amendment to the Company's Amended and Restated Certificate of Incorporation to effect a reverse stock split of the Company common stock at a ratio in the range of 1-for-15 to 1-for-44, with such ratio to be determined in the discretion of the Board and with such reverse stock split to be effected at such time and date, if at all, as determined by the Board in its sole discretion. FOR AGAINST ABSTAIN BROKER NON-VOTES 7,159,500 2,477,700 27,721 0 Proposal 2: To a pprove, in accordance with Nasdaq Listing Rule 563(d), the issuance of more than 19.99% of the Compan

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. APTEVO THERAPEUTICS INC. Date: February 6, 2024 By: /s/ Marvin L. White Marvin L. White President and Chief Executive Officer

View Full Filing

View this 8-K filing on SEC EDGAR